Vaccine and blood products maker CSL has reportedly agreed to settle a major price-fixing class action against the company with a $60 million offer that, if cleared, would end a four-year case initiated by various healthcare groups.
According to reports, US- and Puerto Rico-based health groups involving private hospitals first sued CSL in 2009 accusing the company and others of fixing treatment prices for plasma therapy by colluding to restrict supplies.
CSL continues to deny the allegations, but in a statement said the negotiated settlement was in the best interest of the firm and its shareholders.
Reports say the lawsuit was launched following the US Federal Trade Commission’s blockage of CSL’s attempted takeover of rival Talecris Therapeutics for $3.1 billion, finding the competitors operated as a “tight oligopoly” and manipulated markets.
Full Content: Herald Sun
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI